A m Gliches belimumab problem it is not blocked in April, and can therefore not have sufficient effect on the maturation of B cells TACI Ig con U as a decoy receptor with two anti-BLyS and April work activity. Another agent, inhibits the BAFF-receptor fusion protein Ig only BAFF. TACI-Ig is evaluated in RA and SLE and vorl INDICATIVE studies BIBR 1532 suggest that there is. A significant decrease of serum immunoglobulins BR3 antique Body with anti-cell depletion activity T Fc and BR3 be developed for anything similar indications. The relative merits of strategies with BLyS and April are difficult to compare because their r ‘S Such people are completely not Understood constantly. Lymphotoxin lymphotoxin system, it is also part of the TNF superfamily, and includes a bound ligand inducible lymphotoxin, which competes for binding to the glycoprotein of herpes virus entry mediator T cells, LT D and LT Three ligands bind k can, LT preceptor and can participate in the development of the immune system and lymphoid organization With.
LT lso binds to TNF receptors and their function is blocked by etanercept. Furthermore binds the light to a different receptor herpesvirus entry mediator. LIGHT HVEM interaction is pro-inflammatory, but HVEM also CHIR-99021 binds the B and T lymphocyte attenuator Books that suppress the immune system. Decoy receptor con Us by connecting the LT R with the Fc Dom ne the Ig selectively inhibit pro-inflammatory functions of the LT-system. This strategy is effective in many animal models of autoimmune diseases, including normal CIA and EAE mouse models of lupus and diabetes. R LT signaling the development and maintenance is lympho structures Tertiaries, but is not required for many aspects of lymphocyte biology important High school adults.
In RA, lymphoid structures In the synovial fluid of up to 30% of the patients were observed. LT R Ig therapy can be particularly effective in this sub-population, if these structures play an r Significant role in the local antigen-Pr Presentation and pathogenesis of the disease. Furthermore, to respond to light synoviocytes, LT and LTw ith the release of pro-inflammatory mediators. The first results of RA patients treated with LT R Ig showed some benefit, but a gr Ere study not demonstrated sufficient efficacy to justify the further development of RA. However, other autoimmune diseases such as systemic lupus erythematosus, other indications that could be assessed with this molecule. A sorgf insurance valid monitoring of defense h You will also be required in view of the r Important The LT i n germinal center organization.
Chemokine and chemokine receptor cell recruitment recruitment of inflammatory cells and immune to the target tissue is a characteristic of autoimmune diseases. This process is regulated by a class of proteins called chemokines and many small chemotactic molecules. More than 40 chemokines have been identified and several k Can to multiple receivers singer bind. Additionally Tzlich about half the H 20 of chemokine receptors are seven transmembrane G-protein-coupled receptors, whether recogn Several chemokines. The chemokine receptor or block in a particular disease remains a difficult issue, and targeting individual chemokines was not successful due to the redundancy of the system. On the other side has blocking chemokine GPCR by synthesis of low molecular weight inhibitors which the interaction of multiple chemokines with an individual receiver block singer been encouraging.